Market Overview

Auxilium Pharmaceuticals and FCB I File Lawsuit Against Watson for Infringement of Testim Patents

Share:
Related AUXL
Drug ETFs Attractive Buys On Pullback
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and FCB I LLC announced today that they filed a lawsuit against Watson Laboratories, Inc. (NV); Watson Pharmaceuticals, Inc. (NYSE: WPI); and Watson Pharma, Inc. for infringement of FCB's ten patents listed in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations as covering Testim® 1% testosterone gel.

The lawsuit was filed in the United States District Court for the District of New Jersey on May 23, 2012.

Posted-In: News FDA Legal

 

Related Articles (AUXL + WPI)

Get Benzinga's Newsletters